WO2023037333 - CD33 X Vδ2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER
National phase entry:
Publication Number
WO/2023/037333
Publication Date
16.03.2023
International Application No.
PCT/IB2022/058572
International Filing Date
12.09.2022
Title **
[English]
CD33 X Vδ2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER
[French]
ANTICORPS MULTISPÉCIFIQUES CD33 X VΔ2 POUR TRAITER LE CANCER
Applicants **
JANSSEN BIOTECH, INC
800/850 Ridgeview Drive
Horsham, Pennsylvania 19044, US
Inventors
DOONAN, Patrick John
c/o: Janssen Research & Development, LLC
920 US Route 202
PO Box 300
Raritan, New Jersey 08869, US
LA PORTE, Sherry Lynn
Janssen Research & Development, LLC
920 US Route 202
PO Box 300
Raritan, New Jersey 08869, US
SINGH, Sanjaya
Janssen Research & Development, LLC
920 US Route 202
PO Box 300
Raritan, New Jersey 08869, US
PARREN, Paul Willem Henri Ida
c/o: Lava Therapeutics N.V.
Yalelaan 62
3584 CM Utrecht, NL
MERAT, Sabrina Julia Louisa
c/o: Lava Therapeutics N.V.
Yalelaan 62
3584 CM Utrecht, NL
ROOVERS, Robertus Cornelis
c/o: Lava Therapeutics N.V.
Yalelaan 62
3584 CM Utrecht, NL
ELASHKAR, Sara Mohamed A
c/o: Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse, BE
PHILIPPAR, Ulrike
c/o: Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse, BE
Priority Data
63/243,493
13.09.2021
US
21202685.0
14.10.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1957 | |
| EPO | Filing, Examination | 10340 | |
| Japan | Filing | 593 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 6310 |
Total: 19807 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention relates to multispecific antibodies and pharmaceutical compositions comprising said antibodies, to processes for the preparation of said antibodies and to the use of said antibodies targeting CD33 and to their use in the treatment of diseases, e.g., cancer.[French]
L'invention concerne des anticorps multispécifiques et des compositions pharmaceutiques comprenant lesdits anticorps, des procédés de préparation desdits anticorps et l'utilisation desdits anticorps ciblant CD33 et leur utilisation dans le traitement de maladies, par exemple le cancer.